| View |
|
DRP-16391
|
Iron Sucrose (as Ferric Hydroxide Sucrose Complex)
|
Surcon
|
20 mg/mL (100 mg/5 mL)
|
Solution for Injection (IV)
|
Anti-anemia
|
Makcur Laboratories Limited
|
India
|
Initial
|
26 February 2025
|
26 February 2030
|
| View |
|
DRP-16380
|
Paracetamol + Phenylephrine HCl + Chlorphenamine
Maleate
|
Fluaid
|
500 mg/10 mg/2 mg
|
Tablet
|
Analgesic Antipyretic/Nasal Decongestant/Antihistamine
|
Diamond Laboratories Inc.
|
Philippines
|
Initial
|
25 February 2025
|
25 February 2030
|
| View |
|
DRP-162392
|
Fulvestrant
|
Femcord
|
250 mg/5 mL
|
Solution For Injection (Im/Iv Prefilled Syringe)
|
Anti-estrogen
|
Intas Pharmaceutical Limited
|
India
|
Initial (Re-application)
|
28 February 2025
|
28 February 2030
|
| View |
|
DRP-16360
|
Multivitamins + Minerals.
|
Efergen
|
Formulation:
Each Effervescent Tablet contains:
Ascorbic Acid (Vit. C)
Calcium (as calcium carbonate and calcium pantothenate)
500 mg 100 mg
Magnesium (as magnesium carbonate heavy and magnesium sulphate)
100 mg
50 mg
Nicotinamide (Vit. B3)
Pantothenic acid (as calcium Pantothenate) (Vit. B5)
23 mg
Thiamine Hydrochloride (Vit. B1)
15 mg
Riboflavin (as riboflavin sodium phosphate) (Vit. B2)
15 mg
10 mg
10 mg
Pyridoxine Hydrochloride (Vit. B6)
Zinc (as zinc citrate dihydrate)
Folic Acid
Biotin (Vit. H)
Cyanocobalamin (Vit. B12)
|
Effervescent Tablet
|
Vitamin & Minerals
|
Azarias Pharmaceutical Laboratories Inc.,
|
Philippines
|
Initial
|
28 February 2025
|
28 February 2027
|
| View |
|
DRP-16361
|
Multivitamins + Minerals + Lutein + Lycopene
|
Centrogen Advance
|
4000 IU/ 600 mcg/ 500 mcg/ 2.18 mg/ 3.2 mg/ 15 mg/ 10 mg/ 6 mg/ 45 mcg/ 400 mcg/ 22 mcg/ 90 mg/ 600 IU/ 50 IU/ 25 mcg/ 200 mg/ 35 mcg/ 500 mcg/ 150 mcg/ 5 mg/ 50 mg/ 3.5 mg/ 50 mg/ 80 mg/ 55 mcg/ 7.5 mg
|
Film-Coated Tablet
|
Azarias Pharmaceutical Laboratories Inc.
|
Azarias Pharmaceutical Laboratories Inc.,
|
Philippines
|
Initial
|
28 February 2025
|
28 February 2027
|
| View |
|
DRP-16407
|
Guaifenesin + Phenylpropanolamine HC1 Chlorphenamine Maleate
|
Pluragen
|
100 mg 6.5 mg/2 mg per 45 mL
|
Syrup (Cherry Flavor)
|
Antihistamine/Nasal Decongestant/Expectorant
|
Azarias Pharmaceutical Laboratories
|
Philippines
|
Initial
|
04 March 2025
|
04 March 2030
|
| View |
|
DRP-16236
|
Carmellose Sodium
|
Blysod
|
5 mg/mL (0.5% w/v)
|
Ophthalmic Solution (Eye Drops)
|
Eye Lubricant
|
Makcur Laboratories Limited
|
India
|
Initial
|
27 February 2025
|
27 February 2030
|
| View |
|
DRHR-2410
|
Isopropyl Alcohol
|
Pureshield
|
70 mL per 100 mL (70% v/v Solution)
|
Scented
|
Antiseptic/Disinfectant
|
Medipak Manufacturing Inc.
|
Philippines
|
Initial
|
25 February 2025
|
25 February 2027
|
| View |
|
DRP-16406
|
Paracetamol Chlorpheniramine Maleate
|
Saphcolgen
|
325 mg/20 mg/1 mg
|
Tablet
|
Analgesic/Antipyretic/Nasal Decongestant/
Antihistamine
|
Sapphire Lifesciences Pvt. Ltd.
|
India
|
Initial
|
04 March 2025
|
04 March 2030
|
| View |
|
DRP-16421
|
Cefotaxime (as sodium)
|
Fortaxime
|
1 g
|
Powder for Injection (IM/IV)
|
Antibacterial (Third-generation Cephalosporin)
|
Reyoung Pharmaceutical Co., Ltd
|
China
|
Initial
|
05 March 2025
|
05 March 2030
|
| View |
|
DRP-16422
|
Ceftazidime (as pentahydrate with sodium carbonate)
|
Tarzidime
|
1 g
|
Powder for Injection (IM/IV)
|
Antibacterial (Third-generation Cephalosporin)
|
Reyoung Pharmaceutical Co., Ltd
|
China
|
Initial
|
05 March 2025
|
05 March 2030
|
| View |
|
DRP-16402
|
Metoclopramide hydrochloride
|
Saphmetoc
|
5 mg/mL (10 mg/2 mL)
|
Solution for Injection
(I.M./I.V.)
|
Propulsive
|
Kilitch Drugs (India) Ltd.
|
India
|
Initial (Re-application)
|
03 March 2025
|
03 March 2030
|
| View |
|
HRP-671
|
Ethyl Alcohol
|
None
|
70 mL per 100 mL (70% v/v Solution)
|
Solution
|
Antiseptic/Disinfectant
|
Diamond Laboratories Inc.
|
Philippines
|
Initial
|
25 February 2025
|
25 February 2030
|
| View |
|
DRP-16382
|
Sitagliptin (as phosphate monohydrate)
|
Gliptanova-100
|
100mg
|
Film-Coated Tablet
|
Dipeptidyl peptidase 4 (DDP-4) Inhibitor
|
Eskayef Pharmaceuticals Limited
|
Bangladesh
|
Initial (Re-application)
|
28 February 2025
|
28 February 2030
|
| View |
|
DRP-16383
|
Sitagliptin (as phosphate monohydrate)
|
Gliptanova-50
|
50 mg
|
Film Coated Tablets
|
Dipeptidyl peptidase 4 (DDP-4) Inhibitor
|
Eskayef Pharmaceuticals Limited
|
Bangladesh
|
Initial (Re-application)
|
28 February 2025
|
28 February 2030
|
| View |
|
DRP-16393
|
Ivabradine (as hydrochloride)
|
Ivab-5
|
5mg
|
Film-Coated Tablet
|
Anti-angina
|
Bafna Pharmaceuticals Limited
|
India
|
Initial (Re-application)
|
26 February 2025
|
26 February 2030
|
| View |
|
DR-XY49343
|
Linagliptin
|
Trajenta
|
5 mg
|
Film-Coated Tablet
|
Antidiabetic (Dipeptidyl peptidase 4 (DPP-4)
|
Dragenopharm Apotheker Püschl GmbH
|
Germany
|
Initial (Re-application)
|
26 February 2025
|
26 February 2030
|
| View |
|
DRP-16385
|
Ursodeoxycholic Acid
|
Ursactive
|
500 mg
|
Film-Coated Tablet
|
Bile Salts
|
Pharmactive Ilac San. Ve Tic. A.S
|
Turkey
|
Initial
|
28 February 2025
|
28 February 2030
|
| View |
|
DRP-16408
|
Ticagrelor
|
Tgson-90
|
90 mg
|
Film-Coated Tablet
|
Antithrombotic Agent (Platelet aggregation inhibitor)
|
Unison Pharmaceuticals Pvt. Ltd.
|
India
|
Initial
|
04 March 2025
|
04 March 2030
|
| View |
|
DRP-16395
|
Febuxostat
|
Febufast 40
|
40 mg
|
Film-Coated Tablet
|
Anti-gout (Preparation Production)
|
MSN Laboratories Private Limited (Formulations
Division)
|
India
|
Initial (Re-application)
|
04 March 2025
|
04 March 2030
|